Nimenrix: new conjugate meningitis vaccine

Nimenrix is now available for active immunisation against invasive disease caused by Neisseria meningitidis serogroups A, C, W-135 and Y.

Nimenrix is the first quadrivalent meningococcal conjugate vaccine that is approved for use from 1 year of age
Nimenrix is the first quadrivalent meningococcal conjugate vaccine that is approved for use from 1 year of age


Nimenrix is a conjugated quadrivalent meningitis vaccine consisting of four capsular polysaccharide groups conjugated to tetanus toxoid carrier protein. It induces the production of antibodies against capsular polysaccharides of Neisseria meningitidis group A, C, W135 and Y. These antibodies protect against meningococcal disease via complement-mediated bactericidal activity.1


The safety and efficacy of Nimenrix have been evaluated in 17 clinical studies conducted in 17 countries worldwide. Immunogenicity was assessed in six key studies: two studies recruited infants 12–23 months, two studies enrolled children aged 2–10 years of age, and two studies enlisted adolescents aged 11–17 years and adults aged 18–55 years.1

These key studies aimed to demonstrate a non-inferior immunological response to a single dose of Nimenrix compared with a licensed meningococcal vaccine. Serum bactericidal antibody levels were measured by assays using either rabbit or human complement (rSBA or hSBA).1

In all studies, Nimenrix was found to be non-inferior to a licensed meningococcal vaccine in eliciting an immunological response.1

The safety profile of Nimenrix is based on clinical studies involving more than 8,000 patients. The vaccine was generally well tolerated, with the most commonly observed adverse effects including anorexia, irritability, fatigue, drowsiness, headache, fever and injection-site reactions.1


  1. Nimenrix Summary of Product Characteristics, April 2012.

View Nimenrix drug record

Further information: GlaxoSmithKline

MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.